CoChat
Sign Up
Cited by 30Chronic Obstructive Pulmonary Disease (COPD) ResearchHeart Failure Treatment and ManagementPulmonary Hypertension Research and Treatments

Chronic Obstructive Pulmonary Disease and Heart Failure

Open access
Pellicori, Pierpaolo, Cleland, John G.F., Clark, Andrew L.·2020·Heart Failure Clinics
DOI 10.1016/j.hfc.2019.08.003
Open this paper in CoChat — free accountOpen PDF

Abstract

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are both common causes of breathlessness and often conspire to confound accurate diagnosis and optimal therapy. Risk factors (such as aging, smoking, and obesity) and clinical presentation (eg, cough and breathlessness on exertion) can be very similar, but the treatment and prognostic implications are very different. This review discusses the diagnostic challenges in individuals with exertional dyspnea. Also highlighted are the prevalence, clinical relevance, and therapeutic implications of a concurrent diagnosis of COPD and HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.hfc.2019.08.003

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Symptoms such as dyspnea and wheezing, which are commonly linked to COPD, can also occur in other conditions like CHF, asthma, lung cancer, pneumonia, and interstitial lung diseases.

    “Symptoms such as dyspnea and wheezing, which are commonly linked to chronic obstructive pulmonary disease (COPD), can also occur in other conditions like congestive heart failure (CHF), asthma, lung cancer, pneumonia, and interstitial lung diseases [126,127].”

    From Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors (2026) · cites this paper as [127]

    The Introduction and Synopsis state that breathlessness (dyspnea) is common to COPD and heart failure, supporting that part of the claim. The passages do not establish that wheezing occurs across the listed conditions or identify asthma, lung cancer, pneumonia, and interstitial lung diseases as alternatives; searches for those terms found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 72 · Cited by 30

Research works printed but not linked: 70

  1. [1]Peña VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981-9.
  2. [2]van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16:772-7.
  3. [3]Ponikowski P, Voors AA, Anker SD, et al.; Authors/Task Force Members.; Document Reviewers.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891-975.
  4. [4]Calzetta L, Rogliani P, Matera MG, Cazzola M.A Systematic Review With MetaAnalysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016;149:1181-96.
  5. [5]Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation? JAMA. 1995;273:313-9.
  6. [6]Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019 Jan 22. doi: 10.1002/ejhf.1383. [Epub ahead of print] · DOI
  7. [7]Sze S, Pellicori P, Kamzi S, Anton A, Clark AL. Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure. Int J Cardiol. 2018;264:104112.
  8. [8]Sze S, Pellicori P, Kazmi S, et al. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index. JACC Heart Fail. 2018;6:476-486.
  9. [9]Clark AL, Coats AJ. Unreliability of cardiothoracic ratio as a marker of left ventricular impairment: comparison with radionuclide ventriculography and echocardiography. Postgrad Med J. 2000;76(895):289-91.
  10. [10]Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312:222.
  11. [11]Larssen MS, Steine K, Hilde JM, et al. Mechanisms of ECG signs in chronic obstructive pulmonary disease. Open Heart. 2017;4:e000552.
  12. [13]Woodruff PG, Barr RG, Bleecker E, et al.; SPIROMICS Research Group. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016;374:1811 -1821.
  13. [14]Aaron SD, Tan WC, Bourbeau J, et al.; Canadian Respiratory Research Network. Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. Am J Respir Crit Care Med. 2017;196:306-314.
  14. [15]Perez-Padilla R, Wehrmeister FC, Montes de Oca M, et al.; PLATINO group. Instability in the COPD diagnosis upon repeat testing vary with the definition of COPD. PLoS One. 2015;10:e0121832.
  15. [16]Regan EA, Lynch DA, Curran-Everett D, et al.; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med. 2015; 175:1539-49.
  16. [17]Zhang J, Pellicori P, Pan D, Dierckx R, Clark AL, Cleland JGF. Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure. Int J Cardiol. 2018;269:196-200.
  17. [18]Cleland JG, Pellicori P. Defining diastolic heart failure and identifying effective therapies. JAMA. 2013;309:825-6.
  18. [19]Rutten FH, Cramer MJ, Zuithoff NP et al. Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007;9:651-9.
  19. [20]Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008;177:743-51.
  20. [21]Gale CP, White JE, Hunter A, et al. Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment. J Cardiovasc Med (Hagerstown). 2011;12:613-8
  21. [22]Macchia A, Rodriguez Moncalvo JJ, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012;39:51-8.
  22. [23]Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chron Respir Dis. 2017;14:117-126.
  23. [24]Hawkins NM, Khosla A, Virani SA, McMurray JJ, FitzGerald JM.B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med. 2017;17:11.
  24. [25]Adamson PD, Anderson JA, Brook RD, et al. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol. 2018;72:1126-1137.
  25. [26]Freixa X, Portillo K, Paré C, et al; PAC-COPD Study Investigators.Echocardiographic abnormalities in patients with COPD at their first hospital admission.Eur Respir J. 2013;41:784-91.
  26. [27]Houben-Wilke S, Spruit MA, Uszko-Lencer NHMK, et al. Echocardiographic abnormalities and their impact on health status in patients with COPD referred for pulmonary rehabilitation. Respirology. 2017;22:928-934.
  27. [28]Pellicori P, Cleland JG, Zhang J et al. Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure. Cardiovasc Drugs Ther. 2016;30:599-609.
  28. [29]Divo M, Cote C, de Torres JP, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155-61.
  29. [30]Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80:112-9.
  30. [31]Curkendall SM, DeLuise C, Jones JK, et al.Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70.
  31. [32]Holguin F, Folch E, Redd SC, Mannino DM.Comorbidity and mortality in COPDrelated hospitalizations in the United States, 1979 to 2001. Chest. 2005;128:2005-11.
  32. [33]McCullough PA, Hollander JE, Nowak RM, et al; BNP Multinational Study Investigators. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10:198-204.
  33. [34]Spece LJ, Epler EM, Donovan LM, et al. Role of Comorbidities in Treatment and Outcomes after Chronic Obstructive Pulmonary Disease Exacerbations. Ann Am Thorac Soc. 2018;15:1033-1038.
  34. [35]Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW.The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail. 2009;11:1182-8.
  35. [36]Kaszuba E, Odeberg H, Råstam L, Halling A.Impact of heart failure and other comorbidities on mortality in patients with chronic obstructive pulmonary disease: a register-based, prospective cohort study. BMC Fam Pract. 2018;19:178.
  36. [37]De Blois J, Simard S, Atar D, Agewall S; Norwegian Heart Failure Registry. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16:225-9.
  37. [38]Mentz RJ, Schmidt PH, Kwasny MJ, et al.The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail. 2012;18:515-23.
  38. [39]Canepa M, Straburzynska-Migaj E, Drozdz J, et al; ESC-HFA Heart Failure LongTerm Registry Investigators. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20:100-110.
  39. [40]Canepa M, Temporelli PL, Rossi A, et al; GISSI-HF Investigators. Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology. 2017;136:128-137.
  40. [41]Tavazzi L, Swedberg K, Komajda M, et al; SHIFTInvestigators. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.Int J Cardiol. 2013;170:182-8.
  41. [42]Parissis JT, Andreoli C, Kadoglou N, et al. Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol. 2014;103:733-41.
  42. [43]Mentz RJ, Fiuzat M, Wojdyla DM, et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.Eur J Heart Fail. 2012;14:395-403.
  43. [44]Cuthbert JJ, Kearsley JW, Kazmi S, et al.The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clin Res Cardiol. 2019;108:185-193
  44. [45]Jacob J, Tost J, Miró Ò, Herrero P, Martín-Sánchez FJ, Llorens P; ICA-SEMES Research Group.Impact of chronic obstructive pulmonary disease on clinical course after an episode of acute heart failure. EAHFE-COPD study.Int J Cardiol. 2017;227:450-456.
  45. [46]Iversen KK, Kjaergaard J, Akkan D, et al; ECHOS Lung Function Study Group.The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;12:685-91.
  46. [47]Plesner LL, Dalsgaard M, Schou M, et al.The prognostic significance of lung function in stable heart failure outpatients. Clin Cardiol. 2017;40:1145-1151.
  47. [48]Yoshihisa A, Takiguchi M, Shimizu T, et al.Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol. 2014;64:256-64.
  48. [49]Pellicori P, Salekin D, Pan D, Clark AL.This patient is not breathing properly: is this COPD, heart failure, or neither? Expert Rev Cardiovasc Ther. 2017;15:389-396.
  49. [50]Brenner S, Güder G, Berliner D, et al. Airway obstruction in systolic heart failure-COPD or congestion? Int J Cardiol. 2013;168:1910-6.
  50. [51]Krahnke JS, Abraham WT, Adamson PB, et al; Champion Trial Study Group. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. J Card Fail. 2015;21:240-9.
  51. [52]Lawson CA, Mamas MA, Jones PW, et al. Association of Medication Intensity and Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. JAMA Netw Open. 2018;1:e185489.
  52. [53]Kapoor JR, Kapoor R, Ju C, Heidenreich PA, et al. Precipitating Clinical Factors, Heart Failure Characterization,and Outcomes in PatientsHospitalized With Heart Failure With Redu ced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail. 2016;4:464-72.
  53. [54]Platz E, Jhund PS, Claggett BL, et al. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail. 2018;20:295-303.
  54. [55]Arrigo M, Gayat E, Parenica J, et al; GREAT Network. Precipitating factors and 90day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail. 2017;19:201-208.
  55. [56]Cleland JGF, Bunting KV, Flather MD, at al; Beta-blockers in Heart Failure Collaborative Group.Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26-35.
  56. [57]Hawkins NM, MacDonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684-90.
  57. [58]Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-7.
  58. [59]Düngen HD, Apostolovic S, Inkrot S, et al; CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13:670-80.
  59. [60]Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail. 2018;20:548-556.
  60. [61]Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014;9:e113048.
  61. [62]Bhatt SP, Wells JM, Kinney GL, et al; COPDGene Investigators. β -Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71:814.
  62. [63]Byrd JB, Newby DE, Anderson JA, et al; SUMMIT Investigators. Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J. 2018;39:3128-3134.
  63. [64]Bhatt SP, Connett JE, Voelker H, et al. β -Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease ( β LOCK COPD): a randomised controlled study protocol. BMJ Open. 2016;6:e012292.
  64. [65]Salpeter SR, Ormiston TM, Salpeter EE.Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:230921.
  65. [66]Gershon A, Croxford R, Calzavara A, et al.Cardiovascular safety of inhaled longacting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175-85.
  66. [67]Bermingham M, O'Callaghan E, Dawkins I, et al. Are beta2 agonists responsible for increased mortality in heart failure? Eur J Heart Fail. 2011;13:885-91.
  67. [68]Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus longacting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;12:CD012620.
  68. [69]Ericson-Neilsen W, Kaye AD.Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203-7.
  69. [70]Magnussen H, Disse B, Rodriguez-Roisin R et al; WISDOM Investigators.Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285-94.
  70. [71]Chapman KR, Hurst JR, Frent SM, et al. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med. 2018;198:329-339.

Authors
Pellicori, P., Cleland, J. G. F., & Clark, A. L.
Affiliations
  • University of Glasgow (GB)
  • University of Hull (GB)
Corresponding author
Pellicori, Pierpaolo
ORCID
Venue
Heart Failure Clinics
Publisher
Elsevier BV
Published
2020-01
Volume
16
Issue
1
Pages
33-44
ISSN
1551-7136 (ISSN-L)
DOI
10.1016/j.hfc.2019.08.003
OpenAlex
W2971586858
Cited by
30
References
72
Citations by year
2026: 2 · 2025: 7 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 4
FWCI
0.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Heart Failure Clinics (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
chronic obstructive pulmonary disease, heart failure, exertional dyspnea, dyspnea, differential diagnosis, comorbidities, risk factors, prognosis, therapeutic implications
MeSH terms
Dyspnea, Electrocardiography, Heart Failure, Humans, Risk Factors, Spirometry, Radiography, Thoracic, Global Health, Comorbidity, Prevalence, Pulmonary Disease, Chronic Obstructive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review